StatLab is taking a significant step in advancing pathology with the U.S. launch of Diapath’s innovative instruments, which aligns with our strategic vision post-acquisition.
MCKINNEY, Texas–(BUSINESS WIRE)–StatLab Medical Products, a leading developer and manufacturer of pathology supplies and equipment, today announced the U.S. commercial launch of Diapath signature Pathology instruments. This milestone fulfills the strategic vision behind StatLab’s 2024 acquisition of Diapath: to bring differentiated histology instrumentation to U.S. laboratories and deliver a comprehensive end-to-end pathology workflow solution. These highly innovative instruments—designed to
Source: Original Press Release